Renata PLC has launched Parkadin, the first and only registered generic version of Amantadine 100mg capsules in Finland, alongside simultaneous launches in Denmark, Sweden and Norway, marking a significant milestone in the company's international expansion strategy.
Manufactured at Renata's EU GMP-certified Rajendrapur General Facility, the dopaminergic medicine is indicated for the symptomatic treatment of Parkinson's disease, either as monotherapy or in combination with Levodopa.
Parkadin will be distributed via a strategic partnership using a common pack for the Nordic region, improving access to reimbursed medicines and reducing patients' out-of-pocket expenses.
The launch strengthens Renata's expanding presence in Europe, building on its established position with Amantadine in the UK and EU markets, and further establishing the company as a global pharmaceutical manufacturer providing high-quality, affordable medicines.